The US regulators, on Friday, approved the expansion of fish oil-based drugs to prevent serious cardiac problems in high-risk patients already consuming cholesterol-lowering drugs. Vascepa has approved a few years ago for patients with high triglycerides. Triglyceride is a type of fat in the blood. The U.S. Food and Drug Administration (FDA) allows vascepa use in adults with higher but less extreme triglyceride levels; these extreme levels have multiple risk factors, such as heart disease and diabetes. Inpatient tests, vascepa reduces the risk of fatal complications, including heart attacks and strokes, by about 25%.
Mr. Amarin, the creator of the drug, set the price at US$ 303.65 per month. Patients will pay differently for insurance, and Amarin said it would also provide financial assistance. The Irish drugmaker estimates that the newly approved product could give Vascepa the name ‘vas-EE-puh,’ also known as icosapent ethyl, for up to 15 million American patients. High triglyceride levels can block arteries and increase heart disease, cause heart attack, also requires bypassing or arterial blood removal procedures, or the chance of being hospitalized for chest pain, just like high cholesterol and high blood pressure. Mr. Amarin has funded a five-year study of nearly 8,200 patients with high heart risk who are already taking medications, which lowers the cholesterol levels. Compared to those who added mineral oil fake capsules to the drug. Consuming half of Vascepa capsules with these drugs reduced the risk of heart complications by 25% and reduced the risk of death by 20%. Compared with patients taking fake pills, patients taking Amarin medications had slightly more arrhythmias, but lower side effects. Previous studies that tested other fish oil drugs to reduce heart risk have failed.
According to the American Heart Association, heart disease is estimated to affect 121 million American adults. It also caused deaths, and cost more than $ 500 billion a year in treatment. Millions of Americans take fish oil supplements, also known as omega-3 fatty acids, because they are good for the heart, but their dosage is much lower than Vascepa’s efficacy. Vascepa’s sales in the first nine months of 2019 alone brought in US $287 million for Mr. Amarin.